Pharmacologic profile of survivors of acute myocardial infarction at United States academic hospitals

American Heart Journal
B G PhillipsJ L Bauman

Abstract

Optimal drug therapy for patients with acute myocardial infarction (AMI) is well described in the medical literature. However, data on the actual pharmacologic management of patients surviving AMI at academic hospitals is unavailable. The purpose of this study was to document treatment profiles in 500 patients surviving AMI at 12 academic hospitals in the United States. These profiles were compared with established guidelines and were evaluated for trends. Overall, thrombolytics (streptokinase > or = tissue-type plasminogen activator) were administered in 29% of the patients, with a greater proportion of patients receiving beta-blockers than calcium channel antagonists in the initial 72 hours (61% vs 40%; p < 0.005) and at discharge (51% vs 35%; p < 0.005). Further, women were less likely than men to receive thrombolytic therapy (odds ratio [OR] = 0.61; confidence interval [CI], 0.54 to 0.69) or beta-blocker therapy within the first 72 hours (OR = 0.61; CI, 0.55 to 0.67) or at hospital discharge (OR = 0.53; CI, 0.48 to 0.58). Overall, improvements could still be made in the number of patients who receive thrombolytic and acute and chronic beta-blocker therapies after AMI, particularly in women. Changes in treatment profiles may...Continue Reading

References

Jan 27, 1975·JAMA : the Journal of the American Medical Association
Jul 23, 1992·The New England Journal of Medicine·J LauT C Chalmers
Dec 15, 1990·Annals of Internal Medicine·D W Muller, E J Topol
Aug 18, 1988·The New England Journal of Medicine·UNKNOWN Multicenter Diltiazem Postinfarction Trial Research Group
Apr 2, 1981·The New England Journal of Medicine·UNKNOWN Norwegian Multicenter Study Group
Jun 1, 1995·The American Journal of Cardiology·J M YimP H Vlasses
Sep 2, 1993·The New England Journal of Medicine·UNKNOWN GUSTO investigators
Sep 1, 1993·The American Journal of Cardiology·S A RobertsP H Vlasses

❮ Previous
Next ❯

Citations

Feb 12, 2002·European Journal of Internal Medicine·Andreas SpiessKarin Fattinger
Apr 23, 1999·International Journal of Cardiology·A ErginS Cetin
Apr 26, 2003·International Journal of Cardiology·Pedro Marques-VidalJean Ferrières
Jan 27, 2004·The Annals of Pharmacotherapy·Matthew J EverlyRobert J Cluxton
Aug 17, 2004·Journal of Cardiovascular Pharmacology and Therapeutics·Jerry L Bauman, Robert L Talbert
Jan 7, 1998·The Annals of Pharmacotherapy·P H Vlasses, C J Adarmes

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.